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The discovery that the Duffy antigen was
a promiscuous chemokine binding pro-
tein was entirely serendipitous and resulted
from research begun at Genentech in 1991.
The company had a strong interest in
chemokines because of their role in disease
and this was furthered by the recent cloning
of two chemokine receptors CXCR1 and
CXCR2. Both were IL-8 (CXCL8) recep-
tors expressed on immune cells, primarily
neutrophils, and belonged to the G-protein
coupled receptor (GPCR) subfamily, which
were highly druggable targets. Numerous
reports linked CXCL8 to respiratory dis-
eases like COPD, and Genentech had devel-
oped a CXCL8 neutralizing antibody that it
thought might be useful therapeutically to
treat respiratory diseases like emphysema,
bronchitis, and COPD.
Because a number of signal-
transmitting polypeptides such as human
growth hormone and somatomedin are
bound to plasma binding proteins, it was
of interest to determine whether blood
contained a CXCL8-binding protein. To
determine this Walter Darbonne and Car-
oline Hèbert working in Joffre Bakers lab
at Genentech set up a CXCL8 whole blood
assay in which increasing amounts of radi-
olabeled 125I-CXCL8 were added to whole
blood (1). Interestingly, at low CXCL8 con-
centrations, the recovery of the chemokine
in the plasma was very low but it increased
as the CXCL8 concentration was increased.
This appeared to be a saturable process
and could result from CXCL8 binding to
a blood protein. Since erythrocytes are
the major cell type in blood, an exper-
iment was set up to examine the effect
of adding increasing amounts of radiola-
beled 125I-CXCL8 to these cells. Using this
assay, it was determined that CXCL8 was
specifically absorbed by erythrocytes in a
saturable manner (1). Furthermore, the
erythrocyte-bound CXCL8 was not able
to activate the neutrophils by engaging
CXCR2 but this process could be reversed
by the addition of excess unlabeled CXCL8.
The molecule binding the CXCL8 on ery-
throcytes was a protein because it was
sensitive to chymotrypsin treatment; how-
ever, trypsin treatment had no effect on
binding of CXCL8 (1). Scatchard binding
experiments revealed that the binding was
saturable and defined by a high affinity
receptor, with a binding K D of 5 nM and
around 2,000 binding sites per red blood
cell. Interestingly, it was not always possi-
ble to successfully detect CXCL8 binding
to blood samples and it appeared that the
blood from these CXCL8 non-responders
was always from African American donors.
Taking all of this information together,
a search of the literature revealed that the
CXCL8-binding protein that was discov-
ered at Genentech had molecular prop-
erties consistent with those described for
a human red blood cell antigen called
the Duffy antigen. The Duffy antigen is
a human erythrocyte blood group anti-
gen that was shown to be a portal of
entry for the malarial parasite P. vivax
(2). A promoter mutation in the GATA
box of the Duffy gene prevents its expres-
sion on erythrocytes (3) and most West
Africans are resistant to P. vivax-induced
malaria because they are homozygous for
this mutation (4). To test the hypothesis
that the CXCL8-binding protein was the
Duffy antigen, we obtained whole blood
from Duffy-positive and Duffy-negative
donors and showed that there was an
absolute correlation of CXCL8 binding to
Duffy-positive but not to Duffy-negative
blood (5). Further, we demonstrated that
the Duffy antigen was a promiscuous
chemokine binding protein binding both
CXC and CC chemokines (5). Based on
these observations, we renamed the Duffy
antigen DARC (Duffy antigen receptor
for chemokines) (6). Recently, a new
nomenclature for atypical non-signaling
chemokine receptors such as DARC was
adopted and approved and DARC is now
known by the acronym ACKR1 (atypical
chemokine receptor 1) (7) However, for the
purpose of this review, we will stick to the
old nomenclature of DARC.
Further work showed that DARC was
expressed in other tissues in the body
including kidney and brain (8, 9). Around
this time, the protein had also just been
sequenced (10) and was shown to be a
member of the GPCR family. We trans-
fected the newly cloned receptor into K562
cells and were able to recapitulate all of
the molecular and functional properties of
the protein (11). Furthermore, chemokine
binding to DARC blocked both the binding
and the infection of human erythrocytes by
the malarial parasite P. vivax (12).
There is a variety of evidence in sup-
port of the idea that DARC on erythro-
cytes can act as a depot for chemokines
reducing their concentration in the circu-
lation (1). In line with this notion, can-
cer patients undergoing IL-1 immunother-
apy were shown to have high erythrocyte
CXCL8 binding compared to plasma lev-
els perhaps indicating a potential protec-
tive role to prevent chemokine activation
of neutrophils and inflammation. In addi-
tion, a recent study examining the influence
of DARC in kidney transplant rejection
in African Americans found that DARC-
negative patients had lower allograft sur-
vival than DARC-positive patients (13)
suggesting to the investigators that perhaps
DARC may attenuate the inflammatory
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effects of chemokines by inactivating
them. Further evidence for the protec-
tive nature of DARC comes from trans-
fusion experiments in which either DARC
wild-type erythrocytes or DARC-negative
erythrocytes were transfused into DARC
wild-type endotoxemic mice. The mice
receiving DARC-negative erythrocytes had
increased neutrophil migration into the
lungs, increases in inflammatory cytokine
concentrations, and increases in lung
microvascular permeability compared with
mice receiving DARC-wild-type erythro-
cytes (14). The authors speculated that the
pulmonary inflammation that appeared to
be induced by a reduction in erythro-
cyte chemokine scavenging in these exper-
iments could translate to an increase in
existing lung inflammation in susceptible
Duffy-negative patients.
The idea that DARC can signal in
direct response to ligand binding is highly
unlikely because although it is a seven-
transmembrane-spanning receptor, most
members of which are GPCRs, DARC lacks
the entire DRYLAIV sequence, a highly
conserved determinant of G-protein cou-
pling found in GPCRs at the boundary
between the third transmembrane domain
and the second intracellular loop. This
sequence plays a crucial role in mediating
GPCR action and its absence in DARC leads
to a failure in its coupling to G-proteins and
thus DARC does not mediate a biological
signal upon direct chemokine binding.
Of course, there is still a formal possi-
bility that DARC can provide an indirect
biological signal in response to chemokine
binding. Some support for this idea is pro-
vided by the observation that DARC is
highly expressed on endothelial cells lin-
ing post-capilliary venules (8). The authors
speculate that its cellular location could be
consistent with a role for DARC in leuko-
cyte trafficking. Arguing against this idea
is the fact that individuals lacking expres-
sion of DARC on erythrocytes appear to
have normal immune function. However,
the finding that DARC is expressed on
the endothelial cells of both Duffy-negative
and -positive individuals (6) suggests that
perhaps DARC expression on endothelial
cells may be more important for its role
in leukocyte trafficking than DARC expres-
sion on erythrocytes. The authors specu-
late that the retention of DARC expres-
sion on endothelial cells in Duffy-negative
FIGURE 1 | Seven transmembrane domain receptors are used as vehicles of entry by infectious
agents. (A)The human chemokine binding protein DARC is expressed on erythrocytes and is used by P.
vivax to gain entry to the cell. It can be inhibited by a monoclonal antibody to DARC, Fy6, and by
chemokines such as CXCL1 and CXCL8. (B)The chemokine receptor CCR5 is used as a co-receptor by
the HIV-1 virus to enter human T cells and monocytes. It can be inhibited by chemokines and by the
CCR5 inhibitor maraviroc. Cluster of differentiation 4 (CD4) is a glycoprotein expressed on the surface
of some immune cells including T lymphocytes. HIV-1 envelope glycoprotein (Env) is responsible for
binding to the receptor (CD4) and the chemokine coreceptors (CCR5 or CXCR4) on the host cell, for
subsequent fusion of the viral and cellular membranes.
individuals hints at the retention of a pos-
sible physiological function in these cells.
One feature that characterizes both signal-
ing receptors and chemokine transporters
is the internalization of bound ligands.
Interestingly, K562 cells transfected with
DARC were shown to be able to induce the
internalization of radiolabeled chemokines
(11). Taken together, these studies suggest
that DARC may have a signaling and/or
transporter-like role in endothelial cells
but that it lacks features associated with
direct ligand-activated G-protein receptor
signaling.
Evidence suggesting a role for DARC
in endothelial cells as a chemokine trans-
porter that can influence leukocyte trans-
migration comes from studies by Rot and
coworkers (15). They have shown that
DARC is involved in the transport of
chemokines across endothelial cells. This
transcytosis of chemokines led to their
apical retention but unlike other decoy
receptors such as D6 (ACKR2) ligand
internalization by DARC did not lead
to chemokine degradation. Thus DARC
appears to function as an endothelial trans-
porter for chemokine ligands and, leads to
chemokine immobilization on apical cell
surfaces. It thus appears to play a critical
role in leukocyte trafficking. The authors
also speculate that DARC on endothe-
lial cells might function as a chemokine
rheostat on the blood–tissue interface by
supporting the placement and function of
suboptimal concentrations of chemokines,
but eliminating their excess (16).
The fact that DARC belongs to a fam-
ily of seven transmembrane domain pro-
teins and that almost 40% of all marketed
medicines interact with this class of pro-
teins strongly suggests that DARC is an
excellent target for successfully develop-
ing therapeutics to treat malaria. A simi-
lar approach has already shown benefit in
treating AIDS. AIDS is a lethal infectious
disease of the immune system caused by
the human immunodeficiency virus (HIV),
which can be viewed as a paradigm for P.
vivax-induced-malaria since like its proto-
zoal counterpart, it requires an interaction
between an HIV protein, the viral glyco-
protein gp120, and either one of the human
chemokine receptors CCR5 or CXCR4.
The discovery that chemokine recep-
tors were major coreceptors for HIV entry
into the cell prompted a number of
pharmaceutical companies to screen for
CCR5 inhibitors. The most successful of
these is a small molecule inhibitor of the
HIV gp120–CCR5 interaction, maraviroc,
which is now a registered drug to treat
AIDS. An approach to identify small mol-
ecule inhibitors of DARC should prove to
be of similar benefit in drastically reducing
P. vivax malaria (Figure 1). Such inhibitors
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could be a valuable addition to drug combi-
nations that target both P. falciparum and
P. vivax in regions of the world that are
endemic for these parasites.
Another interesting parallel between
HIV infection and P. vivax-induced
malaria is that individuals have been iden-
tified who are resistant to infection by one
or the other of these agents. In the case of
HIV, humans with a frameshift mutation
in the coding region of the HIV recep-
tor have been identified. This mutation,
called delta32, results in the premature
truncation of the receptor such that it is
no longer expressed. As a consequence,
homozygous CCR5 delta32 individuals are
resistant to infection by CCR5-tropic HIV
strains. These people, who are essentially
CCR5 knockouts, do not exhibit any obvi-
ous deleterious effects from the lack of this
receptor (except for some reports that they
are more susceptible to brain infection with
West NileVirus),which may be rationalized
by the functional redundancy that seems
to be built into the chemokine system
where several other chemokine receptors
can compensate for a lack of CCR5.
Similarly, individuals in West Africa do
not express DARC on their erythrocytes,
and they are resistant to P. vivax-induced
malaria (4). The parallels to the CCR5
delta32 mutation as a protective factor in
infection by HIV and the successful devel-
opment of a CCR5 inhibitor to treat AIDS
are striking and we envisage that develop-
ment of a DARC inhibitor might also work
for P. vivax-induced malaria.
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